MX2021004007A - Moduladores de linfocitos t reguladores multivalentes. - Google Patents

Moduladores de linfocitos t reguladores multivalentes.

Info

Publication number
MX2021004007A
MX2021004007A MX2021004007A MX2021004007A MX2021004007A MX 2021004007 A MX2021004007 A MX 2021004007A MX 2021004007 A MX2021004007 A MX 2021004007A MX 2021004007 A MX2021004007 A MX 2021004007A MX 2021004007 A MX2021004007 A MX 2021004007A
Authority
MX
Mexico
Prior art keywords
multivalent
regulatory
binding moiety
cell modulators
receptor
Prior art date
Application number
MX2021004007A
Other languages
English (en)
Inventor
Jeffrey Greve
Jungmin Kim
Niranjana Nagarajan
John Cho
Original Assignee
Delinia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delinia Inc filed Critical Delinia Inc
Publication of MX2021004007A publication Critical patent/MX2021004007A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)

Abstract

La presente descripción proporciona compuestos que contienen una porción de unión al receptor de IL-2 y una porción de unión a ST2. Los métodos descritos en la presente descripción proporcionan un método para el tratamiento contra una afección mediante la administración, a un sujeto que lo necesite, de una cantidad terapéuticamente efectiva de un compuesto que contiene una porción de unión al receptor de IL-2 y una porción de unión a ST2.
MX2021004007A 2016-12-13 2019-06-13 Moduladores de linfocitos t reguladores multivalentes. MX2021004007A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662433533P 2016-12-13 2016-12-13

Publications (1)

Publication Number Publication Date
MX2021004007A true MX2021004007A (es) 2021-06-23

Family

ID=62488540

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019007002A MX2019007002A (es) 2016-12-13 2017-12-13 Moduladores de linfocitos t reguladores multivalentes.
MX2021004007A MX2021004007A (es) 2016-12-13 2019-06-13 Moduladores de linfocitos t reguladores multivalentes.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019007002A MX2019007002A (es) 2016-12-13 2017-12-13 Moduladores de linfocitos t reguladores multivalentes.

Country Status (11)

Country Link
US (2) US10472405B2 (es)
EP (1) EP3554525A4 (es)
JP (1) JP7228515B2 (es)
KR (1) KR20190094222A (es)
CN (1) CN110177564A (es)
AU (1) AU2017378308A1 (es)
BR (2) BR122020025384B1 (es)
CA (1) CA3044416A1 (es)
MX (2) MX2019007002A (es)
RU (1) RU2769871C2 (es)
WO (1) WO2018112069A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015042521A1 (en) 2013-09-20 2015-03-26 University Of Virginia Patent Foundation Compositions and methods for treatment of autoimmune and inflammatory diseases and disorders
KR20190094222A (ko) 2016-12-13 2019-08-12 데리니아, 인크. 다가 조절성 t 세포 조절제
AU2018234810B2 (en) 2017-03-15 2023-05-11 Pandion Operations, Inc. Targeted immunotolerance
WO2018217989A1 (en) 2017-05-24 2018-11-29 Pandion Therapeutics, Inc. Targeted immunotolerance
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
CN113651880A (zh) 2018-08-06 2021-11-16 麦地金公司 Il-2受体结合化合物
AU2019369498A1 (en) * 2018-10-31 2021-05-20 Delinia, Inc. Multivalent regulatory T cell modulators
JP2022533702A (ja) 2019-05-20 2022-07-25 パンディオン・オペレーションズ・インコーポレイテッド ＭＡｄＣＡＭ標的化免疫寛容
JP2022536581A (ja) * 2019-06-19 2022-08-18 キュー バイオファーマ， インコーポレイテッド 多量体ｔ細胞調節性ポリペプチド及びその使用方法
CN114853874B (zh) * 2019-09-10 2024-05-17 中国医学科学院北京协和医院 靶向调节t细胞的长效白介素-2及其在治疗自身免疫病中的应用
US11718654B2 (en) 2019-11-05 2023-08-08 Medikine, Inc. IL-2R-βγ binding compounds
AU2020378282B2 (en) 2019-11-05 2023-05-18 Medikine, Inc. Dual IL-2R and IL-7R binding compounds
IL295304A (en) 2020-02-03 2022-10-01 Medikine Inc 7-il alpha gamma c receptor binding compounds, preparations containing them and their uses
AU2021217959A1 (en) 2020-02-03 2022-08-18 Medikine, Inc. IL-7Rα binding compounds
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
US11999771B2 (en) 2022-04-07 2024-06-04 Medikine, Inc. IL-7Rαγc ligand immunoglobulin fusion proteins
WO2023220692A1 (en) * 2022-05-11 2023-11-16 Slate Bio, Inc. Compositions comprising truncated interleukin-33 and interleukin-2

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731168A (en) * 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
DZ2788A1 (fr) * 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
US7754855B1 (en) * 1999-07-13 2010-07-13 Bolder Biotechnology, Inc. Immunoglobulin fusion proteins
AU2004275860A1 (en) 2003-09-23 2005-04-07 Pdl Biopharma, Inc. Treatment of respiratory diseases with anti-IL-2 receptor antibodies
AR091069A1 (es) * 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
CA2878843A1 (en) * 2012-07-13 2014-01-16 Zymeworks Inc. Bispecific asymmetric heterodimers comprising anti-cd3 constructs
KR102264570B1 (ko) * 2012-11-28 2021-06-14 자임워크스 인코포레이티드 가공된 면역글로불린 중쇄-경쇄 쌍 및 이들의 용도
AU2014232416B2 (en) * 2013-03-15 2017-09-28 Xencor, Inc. Modulation of T Cells with Bispecific Antibodies and FC Fusions
WO2015042521A1 (en) * 2013-09-20 2015-03-26 University Of Virginia Patent Foundation Compositions and methods for treatment of autoimmune and inflammatory diseases and disorders
CR20160333A (es) * 2014-02-06 2016-09-05 F Hoffman-La Roche Ag Proteinas de fusión de interleucina-2 y usos de las mismas
CN106795213B (zh) 2014-07-21 2021-12-07 德里尼亚公司 选择性地活化调节性t细胞用于治疗自身免疫病的分子
KR20190094222A (ko) 2016-12-13 2019-08-12 데리니아, 인크. 다가 조절성 t 세포 조절제

Also Published As

Publication number Publication date
CA3044416A1 (en) 2018-06-21
BR122020025384B1 (pt) 2022-07-12
US20180162919A1 (en) 2018-06-14
JP2020501550A (ja) 2020-01-23
US20200031897A1 (en) 2020-01-30
BR112019011799A2 (pt) 2019-10-29
RU2019121902A3 (es) 2021-04-21
JP7228515B2 (ja) 2023-02-24
MX2019007002A (es) 2019-08-22
KR20190094222A (ko) 2019-08-12
US10472405B2 (en) 2019-11-12
EP3554525A4 (en) 2020-08-19
WO2018112069A1 (en) 2018-06-21
RU2019121902A (ru) 2021-01-18
CN110177564A (zh) 2019-08-27
EP3554525A1 (en) 2019-10-23
BR112019011799B1 (pt) 2021-12-21
RU2769871C2 (ru) 2022-04-07
US11059877B2 (en) 2021-07-13
AU2017378308A1 (en) 2019-06-20

Similar Documents

Publication Publication Date Title
MX2021004007A (es) Moduladores de linfocitos t reguladores multivalentes.
MX2021005008A (es) Moduladores de celulas t reguladoras multivalentes.
MX2021002406A (es) Composiciones farmaceuticas que comprenden un inhibidor de il-4r para usarse en el tratamiento de la esofagitis eosinofilica.
PT3456717T (pt) Derivado de 4,6-diamino-quinolina-3-carbonitrilo como modulador do cancro da tiróide de osaka (cot) para o tratamento de doenças inflamatórias
PH12018501669A1 (en) Compositions containing tucaresol or its analogs
MX2021002900A (es) Composicion con complejos de nanoparticulas/anticuerpos de paclitaxel unidos a albumina para usarse al tratar linfoma.
MX2021007651A (es) Inhibidores de ezh2 para tratar linfomas.
MX2015013154A (es) Uso de higado desceluralizado por perfusion para receluralizacion de celulas de islote.
PE20170907A1 (es) Compuestos neuroactivos y metodos de uso de los mismos
PH12016502062A1 (en) Compositions and methods for modulating completent factor b expression
MX2016004540A (es) Tiazolopirimidinonas como moduladores de la actividad de receptores de n-metil-d-aspartato (nmda).
PH12017500533A1 (en) 1-alkyl-6-oxo-1, 6-dihydropyridin-3-yl compounds and use as sgrm modulators
NZ722600A (en) Methods of treating mild brain injury
EA201690014A1 (ru) Популяции клеток, способы трансдифференцировки и способы их применения
UY36292A (es) Compuestos de tetrahidroquinolina para su uso como inhibidores de bromodominios
AU2017245414A1 (en) The cure for cancer
MX2019012659A (es) Metodos para tratar ateroesclerosis con neutralizadores gamma-cetoaldehido.
MX2018012904A (es) Uso de beta-agonistas del receptor de la hormona tiroidea.
EP3327051A4 (en) Polymerizable composition containing polymerizable liquid crystal compound, film, and method for producing film
MX2019015273A (es) Moduladores de alfa-sinucleinca.
MX2019014291A (es) Metodo de tratamiento.
MX2016002307A (es) Tratamiento para el cancer.
EP3424896A4 (en) PROCESS FOR PREPARING A LIQUID COMPOSITION WITH MONOETHERATE, LIQUID COMPOSITION AND METHOD FOR PRODUCING A POLYMERIZABLE COMPOUND
MX2018001221A (es) Composicion farmaceutica con estabilidad de almacenamiento mejorada y metodo para prepararla.
MX2018001219A (es) Composicion farmaceutica con estabilidad de almacenamiento mejorada y metodo para prepararla.